Serum Interleukin-8 Levels Identify Non-Atrial Fibrillation Patients at Risk for Catheterization-Confirmed Diastolic

Zhiyuan Ma1,2, Zhiqiang Yang1, Xiaotong Ji1

  • 1Heart Center, The First Hospital of Hebei Medical University, Hebei Medical University, 89 Donggang Road, Shijiazhuang, 050031, Hebei Province, China.

Insights

Serum interleukin-8 (IL-8) shows promise as an early biomarker for left ventricular diastolic dysfunction (LVDD), a key factor in heart failure with preserved ejection fraction (HFpEF). Combining IL-8 with other markers improves diagnostic accuracy for timely intervention.

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Inflammation Research

Background:

  • Left ventricular diastolic dysfunction (LVDD) is crucial for diagnosing heart failure with preserved ejection fraction (HFpEF).
  • Current noninvasive methods may miss early LVDD, delaying treatment.
  • Interleukin-8 (IL-8) is implicated in inflammation and cardiovascular remodeling, suggesting its potential as an early diagnostic marker.

Purpose of the Study:

  • To investigate serum IL-8 as a potential noninvasive biomarker for early detection of catheterization-confirmed LVDD.
  • To evaluate the diagnostic performance of IL-8, alone and in combination with established markers, for LVDD.

Main Methods:

  • Retrospective cohort study (n=1,014) assessing 12 inflammatory cytokines using flow cytometry.
  • Prospective validation cohort (n=248) to confirm IL-8 findings.
  • Analysis of diagnostic performance using receiver operating characteristic curves (AUC).

Main Results:

  • Serum IL-8 levels were significantly elevated in LVDD patients without atrial fibrillation (2.26-fold increase).
  • IL-8 was independently associated with LVDD in the discovery cohort (adjusted OR: 13.2).
  • Combining IL-8 with B-type natriuretic peptide (BNP) and E/e' ratio improved diagnostic accuracy (AUC: 0.79).

Conclusions:

  • Serum IL-8 is an independent biomarker for diagnosing catheterization-confirmed LVDD in patients without atrial fibrillation.
  • IL-8 enhances diagnostic performance when combined with traditional markers like BNP and E/e'.
  • IL-8 offers a promising tool for early HFpEF identification and risk stratification, aiding in unexplained dyspnea evaluation.